茵芍散治疗慢性乙型肝炎湿热蕴脾证的临床研究
|
摘要
目的：运用具有清热祛湿化瘀功用的茵芍散与湿热中阻证代表方连朴饮进行对照研究，观察茵芍散治疗慢性乙型肝炎湿热蕴脾证患者的临床疗效，探索治疗慢性乙型肝炎湿热蕴脾证的有效治法和方药。
方法：临床诊断为慢性乙型肝炎湿热蕴脾证患者90例，随机分成观察组(茵芍散胶囊联合常规保肝降酶治疗)、中药对照组(连朴饮胶囊联合常规保肝降酶治疗)及常规治疗组(单纯常规保肝降酶治疗)，每组各30例，并以20例健康人为正常对照组。三组疗程均为1个月，治疗前后检测肝功能，病毒复制指标(HBV DNA)，病毒标志物(HBVM)，血清免疫球蛋白IgG、IgM，血清补体C3、C4及外周血单个核细胞(PBMC)培养上清液中两种辅助性T细胞(Th1和Th2)的细胞因子γ干扰素(IFN-γ)和白介素—4(IL-4)，并观察治疗前后中医证候积分变化，用统计学分析三组间各项指标的差异。茵芍散、连朴饮胶囊均做急性毒性试验后使用。
结果：(1)在降低中医证候积分方面，观察组优于中药对照组(P＜0.05)，中药对照组优于常规治疗组(P＜0.05)。三组中医证候疗效比较，以观察组疗效最好(P＜0.05)。(2)三组在改善ALT、AST、TBIL、Alb等肝功能方面，观察组优于中药对照组和常规治疗组(P＜0.05)。(3)在降低HBV DNA方面，观察组优于中药对照组和常规治疗组(P＜0.05)；但在HBsAg、HBeAg阴转及Anti—HBe阳转等方面的差异无统计学意义(P＞0.05)。(4)三组患者IgG、IgM较正常对照组均显著升高(P＜0.01)，三组IgG、IgM治疗前后比较差别均有显著性意义(P＜0.05)，在降低IgG疗效方面观察组优于中药对照组(P＜0.05)，中药对照组优于常规治疗组(P＜0.05)；在降低IgM疗效方面观察组优于其它两组(P＜0.05)。(5)三组患者C3、C4较正常对照组均显著降
低(P<0.01)，三组C3治疗前后比较差别均有显著性意义(P<0.01)，在升高C3疗效
方面观察组优于中药对照组(P<0 .05)，中药对照组优于常规治疗组(P<0 .05);观察
组和中药对照组C4治疗前后比较差别均有显著性意义(P 后比较差别无显著性意义(P>0 .05)，在升高C4疗效方面观察组优于中药对照组(P<
0.05)。(6)与正常对照组比较，三组患者PBMC培养上清液的IFN一Y显著降低(P<
0.01)，IL一4显著升高(P(0.01)。观察组IFN一Y治疗前后比较差别有显著性意义(P(
0.01)，其它两组治疗前后比较差别均无显著性意义(P>0.05)，仅有观察组具有升高
工FN一Y的疗效。观察组和中药对照组丁L一4治疗自1J’后比较差别均有显著性意义(P<
0.01)，常规治疗组治疗前后差别无显著性意义(P>0 .05)，在降低IL一4疗效方而观
察组优于中药对照组(P<0 .05)。
结论:(1)茵芍散可明显改善临床症状，改善肝功能，具有调节体液免疫功能
及Thl/ThZ细胞因子失衡的作用。(2)具有清热祛湿化癖功用的茵芍散在总体疗效上
优于单纯清热祛湿功用的连朴饮，提示治疗慢性乙型肝炎湿热蕴脾证应重视活血化赢
Objective:To observe the curative effect of Yin-shao-san capsule with the function of antipyretic drying damp and blood act stasis remove for patients with dampness-heat retention spleen syndrome of chronic hepatitis B, in comparison with Lian-pu-yin capsule with the function of antipyretic drying damp, and seek after the efficiency therapy and prescription for damp-heat in spleen syndrome of chronic hepatitis B.
Method: ninety patients with dampness-heat retention spleen syndrome of chronic hepatitis B were divided into three groups : observe (OB) group (treated combination of Yin-shao-san capsule and routine drugs) Chinese drugs control (CC) group (treated combination of Lian-pu -yin capsule and routine drugs) and routine treatment (RT) group (only treated routine drugs) , consisted of 30 cases each group , with one month coures of treatment. 20 healthy persons served as normal control (NO group. Before and after treatment the patients' serum biochemical criterion virus replication indes (HBV DNA), viral markers (HBVM), serum immunoglobulin IgG, IgM, serum complement C3 , C4 and the two kinds of cytokines (IFN- r. IL-4) of T helper lymphocyte in peripheral blood mononuclear cell (PBMC) were measured, and the marks of syndrome also were recorded before and after treatment. Before treatment acute toxicity of Yin-shao-san capsule and Lian-pu-yin capsule were also tested.
Results: (1) The curative effect of OB group in decreasing the marks of syndrome was super to CC group (P<0.05) , and CC group was super to RT group (P<0.05) .The
curative effects of OB group in improving symptoms were super to the other two groups
(P<0.05 ).(2)The curative effect of OB group in improving liver function was super to the other two groups (P<0.05). (3) The curative effect of OB group in decreasing HBV DNA was super to the other two groups (P<0.05) , but there were no significantly differences among the three groups in negative conversions of HBsAg, HBeAg and positive conversion of Anti-HBe (P>0.05) . (4) The levels of IgG, IgM were increased significantly (P<0.01) in serum of the patients in comparison with the normal group. The levels of IgG . IgM in serum of the three groups post-treatment were all obviously lower than those of pre-treatment(P<0.05).The curative effect of OB group in decreasing the levels of IgG was super to CC group (P<0.05) ,and CC group was super to RT group (P<0.05 ) .The curative effect of OB group in decreasing the levels of IgM was super to the other two groups
(P<0.05) . (5) The levels of C3> C4 were decreased significantly in serum of the patients in comparison with the normal control (P<0.01) . The levels of C3 in serum of the three groups post-treatment were obviously higher than those of pre-treatment (P<0. 01) , the curative effect of OB group in increasing the levels of C3 was super to CC group (P<0.05), and CC group was super to RT group (P<0.05). The levels of C4 in serum of OB group and CC group post-treatment were obviously higher than those of pre-treatment (P<0. 01) , the curative effect of OB group in increasing the level of C4 was super to CC group (P<0.05) .
(6) The levels of IFN-gamma were decreased significantly (P<0. 01) in the supernatant of PBMC cultures of the patients in comparison with the normal control, and the levels of IL-4 were increased significantly (P<0.01) in comparison with the normal control. The levels of IFN-gamma of OB group post-treatment were obviously higher than those of pre-treatment
(P<0.01), it indicated that only OB group increased the levels of IFN-gamma. The levels of IL-4 of OB group and CC group post-treatment were obviously lower than those of pre-treatment (P<0.01), the curative effect of OB group in decreasing the level of IL-4 was super to CC group (P<0.05) .
Conclusions: (1) Yin-Shao-San capsule was effective in improving the symptoms and liver function, and regulated humoral immunity and the out-of-balance of Th1/Th2 cytokines. (2) Yin-Shao-San capsule with the function of antipyretic drying damp and blood
act stasis remove was
方法：临床诊断为慢性乙型肝炎湿热蕴脾证患者90例，随机分成观察组(茵芍散胶囊联合常规保肝降酶治疗)、中药对照组(连朴饮胶囊联合常规保肝降酶治疗)及常规治疗组(单纯常规保肝降酶治疗)，每组各30例，并以20例健康人为正常对照组。三组疗程均为1个月，治疗前后检测肝功能，病毒复制指标(HBV DNA)，病毒标志物(HBVM)，血清免疫球蛋白IgG、IgM，血清补体C3、C4及外周血单个核细胞(PBMC)培养上清液中两种辅助性T细胞(Th1和Th2)的细胞因子γ干扰素(IFN-γ)和白介素—4(IL-4)，并观察治疗前后中医证候积分变化，用统计学分析三组间各项指标的差异。茵芍散、连朴饮胶囊均做急性毒性试验后使用。
结果：(1)在降低中医证候积分方面，观察组优于中药对照组(P＜0.05)，中药对照组优于常规治疗组(P＜0.05)。三组中医证候疗效比较，以观察组疗效最好(P＜0.05)。(2)三组在改善ALT、AST、TBIL、Alb等肝功能方面，观察组优于中药对照组和常规治疗组(P＜0.05)。(3)在降低HBV DNA方面，观察组优于中药对照组和常规治疗组(P＜0.05)；但在HBsAg、HBeAg阴转及Anti—HBe阳转等方面的差异无统计学意义(P＞0.05)。(4)三组患者IgG、IgM较正常对照组均显著升高(P＜0.01)，三组IgG、IgM治疗前后比较差别均有显著性意义(P＜0.05)，在降低IgG疗效方面观察组优于中药对照组(P＜0.05)，中药对照组优于常规治疗组(P＜0.05)；在降低IgM疗效方面观察组优于其它两组(P＜0.05)。(5)三组患者C3、C4较正常对照组均显著降
低(P<0.01)，三组C3治疗前后比较差别均有显著性意义(P<0.01)，在升高C3疗效
方面观察组优于中药对照组(P<0 .05)，中药对照组优于常规治疗组(P<0 .05);观察
组和中药对照组C4治疗前后比较差别均有显著性意义(P
0.05)。(6)与正常对照组比较，三组患者PBMC培养上清液的IFN一Y显著降低(P<
0.01)，IL一4显著升高(P(0.01)。观察组IFN一Y治疗前后比较差别有显著性意义(P(
0.01)，其它两组治疗前后比较差别均无显著性意义(P>0.05)，仅有观察组具有升高
工FN一Y的疗效。观察组和中药对照组丁L一4治疗自1J’后比较差别均有显著性意义(P<
0.01)，常规治疗组治疗前后差别无显著性意义(P>0 .05)，在降低IL一4疗效方而观
察组优于中药对照组(P<0 .05)。
结论:(1)茵芍散可明显改善临床症状，改善肝功能，具有调节体液免疫功能
及Thl/ThZ细胞因子失衡的作用。(2)具有清热祛湿化癖功用的茵芍散在总体疗效上
优于单纯清热祛湿功用的连朴饮，提示治疗慢性乙型肝炎湿热蕴脾证应重视活血化赢
Objective:To observe the curative effect of Yin-shao-san capsule with the function of antipyretic drying damp and blood act stasis remove for patients with dampness-heat retention spleen syndrome of chronic hepatitis B, in comparison with Lian-pu-yin capsule with the function of antipyretic drying damp, and seek after the efficiency therapy and prescription for damp-heat in spleen syndrome of chronic hepatitis B.
Method: ninety patients with dampness-heat retention spleen syndrome of chronic hepatitis B were divided into three groups : observe (OB) group (treated combination of Yin-shao-san capsule and routine drugs) Chinese drugs control (CC) group (treated combination of Lian-pu -yin capsule and routine drugs) and routine treatment (RT) group (only treated routine drugs) , consisted of 30 cases each group , with one month coures of treatment. 20 healthy persons served as normal control (NO group. Before and after treatment the patients' serum biochemical criterion virus replication indes (HBV DNA), viral markers (HBVM), serum immunoglobulin IgG, IgM, serum complement C3 , C4 and the two kinds of cytokines (IFN- r. IL-4) of T helper lymphocyte in peripheral blood mononuclear cell (PBMC) were measured, and the marks of syndrome also were recorded before and after treatment. Before treatment acute toxicity of Yin-shao-san capsule and Lian-pu-yin capsule were also tested.
Results: (1) The curative effect of OB group in decreasing the marks of syndrome was super to CC group (P<0.05) , and CC group was super to RT group (P<0.05) .The
curative effects of OB group in improving symptoms were super to the other two groups
(P<0.05 ).(2)The curative effect of OB group in improving liver function was super to the other two groups (P<0.05). (3) The curative effect of OB group in decreasing HBV DNA was super to the other two groups (P<0.05) , but there were no significantly differences among the three groups in negative conversions of HBsAg, HBeAg and positive conversion of Anti-HBe (P>0.05) . (4) The levels of IgG, IgM were increased significantly (P<0.01) in serum of the patients in comparison with the normal group. The levels of IgG . IgM in serum of the three groups post-treatment were all obviously lower than those of pre-treatment(P<0.05).The curative effect of OB group in decreasing the levels of IgG was super to CC group (P<0.05) ,and CC group was super to RT group (P<0.05 ) .The curative effect of OB group in decreasing the levels of IgM was super to the other two groups
(P<0.05) . (5) The levels of C3> C4 were decreased significantly in serum of the patients in comparison with the normal control (P<0.01) . The levels of C3 in serum of the three groups post-treatment were obviously higher than those of pre-treatment (P<0. 01) , the curative effect of OB group in increasing the levels of C3 was super to CC group (P<0.05), and CC group was super to RT group (P<0.05). The levels of C4 in serum of OB group and CC group post-treatment were obviously higher than those of pre-treatment (P<0. 01) , the curative effect of OB group in increasing the level of C4 was super to CC group (P<0.05) .
(6) The levels of IFN-gamma were decreased significantly (P<0. 01) in the supernatant of PBMC cultures of the patients in comparison with the normal control, and the levels of IL-4 were increased significantly (P<0.01) in comparison with the normal control. The levels of IFN-gamma of OB group post-treatment were obviously higher than those of pre-treatment
(P<0.01), it indicated that only OB group increased the levels of IFN-gamma. The levels of IL-4 of OB group and CC group post-treatment were obviously lower than those of pre-treatment (P<0.01), the curative effect of OB group in decreasing the level of IL-4 was super to CC group (P<0.05) .
Conclusions: (1) Yin-Shao-San capsule was effective in improving the symptoms and liver function, and regulated humoral immunity and the out-of-balance of Th1/Th2 cytokines. (2) Yin-Shao-San capsule with the function of antipyretic drying damp and blood
act stasis remove was
引文
[1] 骆抗先编著．乙型肝炎基础和临床(M)．第二版．北京：人民卫生出版社，2001：3．
[2] Thomas HC, montano L Goodall A et al. Immunological mechanisms in chronic hepatitis B. Virus infection. Hepatology(J),1983;2 (Suppl) :116-121.
[3] Penna A ,Chisan FV, Bertoletti A et al. cytoxic T lymphocytes recognize an HLA -restricted epitope within the hepatitis B virus nucleocapsid antigen. Exp med(J) 1991, 174:1565-1570.
[4] Bertoletti AK, Elios MM, Boni C, et al. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infection. Gastroenterology (J) , 1997, 112(1) :193-199.
[5] Lee M, Lee SK, Son M, et al. Expression of Th1 and Th2 type cytokines responding to HBsAg and HBxAg in chronic hepatitis B patients. Korean Men Sci(J) .1999,14:175-181.
[6] Nishimura T, Ohta A. A critical role for antigen-specific Th1 cells in acute liver injury in mice. Immunol(J),1999,162:6503-6509.
[7] 陈锦芳，李丹，潘晨等．慢肝湿热蕴脾证血瘀的研究．福建中医学院学报(J)，
2000，10(3)：3-5．
[8]病毒性肝炎防治方案．中华传染病杂志(J)，2001，19(1)：56-62．
[9]中药新药临床研究指导原则(第一辑)(M)．中华人民共和国卫生部制定发布，1993：103-106．
[10]陈奇主编．中药药理实验方法(M)．第一版．北京：人民卫生出版社，1994：23-28．
[11]谢秀琼主编．中药新制剂开发与应用(M)．第二版．北京：人民卫生出版社，2000：534—535，540．
[12]Nayersina R etal. Immune(J), 1993, 150:4659-4671.
[13]Rehermann B etal. Exp Med(J),1995,189:1047-1058.
[14]陈复正．幼幼集成(M)．第一版．上海：上海科学技术出版社，1962：162．
[15]单书健，陈子华编著．古今名医临证金鉴．黄疸胁痛臌胀卷(M)．第一版．北京：中国中医药出版社，1998：60，141．
[16]饶闲宜．病毒性肝炎微循环障碍与瘀血的关系．云南中医(J)，1985，3：1．
[17]廖孔禹．活血化瘀法治疗慢性活动性肝炎140例．四川中医(J)，1987，12：18．
[18]解新科，王静，郝明霞．活血化瘀为主治疗慢性乙肝疗效及血液流变学观察．陕西中医学院学报(J)，1999，22(6)17-18．
[19]张赤志，吴寿善，罗欣拉等．肝病血瘀证临床病理学特点和肝功能变化．中国中西医结合杂志(J)，1992，12(4)：210．
[20]张清波．通过外周微循环、血液流变学和免疫功能的观察探讨病毒性肝炎的中医辨证分型．中华医学杂志(J)，1982，62(8)：449—454．
[21]王伯祥主编．活血化瘀药．中医肝胆病学(M)．第一版．北京：中国医药科技出版社，1998：193
[22]徐树楠主编．中药临床应用大全(M)．第一版．河北：河北科学技术出版社，1999：277，646，89，15，588，254，67，54．
[23]刘国华，王健．茵栀黄口服液对实验性肝损伤的药理作用及毒性研究．中药新药与临床药理(J)，1995，6(2)：28—29．
[24]JP(J)．1982，18：622．
[25]蔡宝昌，潘扬，吴皓等．国外天然药物抗病毒研究简况．国外医学．中医中药分册(J)，1997，19(3)：48．
[26]张赤伟，吴在德．丹参对大鼠肝缺血后残肝再生促进作用的初步观察．同济医科大学学报(J)，1995，24(4)：272．
[27]戚心广，稻恒豐．丹参、赤芍对实验性肝损伤肝细胞保护作用的机理研究．中西医结合杂志(J)，1991，11(2)：102．
[28]张万增，董仲德，袁桂玉等．丹参对重型肝炎补体活化的抑制作用．中国中西医结合杂志(J)，1994，14(7)：445．
[29]何敏．白花蛇舌草的研究与应用概况．中医药学报(J)，1994，22(5)：36-39．
[30]单保思，张金艳，杜肖娜等．白花蛇舌草的免疫学调节活性和抗肿瘤活性．中国中西医结合杂志(J)，2001，21(5)：370-374．
[31]王建军，刑秋侠，郭文化等．乙型肝炎患者补体对HBsAg特异性免疫复合物的裂解作用．中国实用临床免疫学杂志(J)，1998，10(4)：222-226．
[32]董薇红，腾天申，吴昌烈等．13种血清蛋白检测在各型肝炎中的临床意义．中华传染病杂志(J)，1994，12(1)：44-45．
[33]蔡望喜，胡传芳，乐惠荣等．慢性乙肝患者红细胞免疫粘附功能和体液免疫功能的观察．中西结合肝病杂志(J)，1999，9(1)：38-39．
[34]高寿征，田庚善，崔振宇等主编．病毒性肝炎防治研究(M)．北京：北京出版社，1993：182，88．
[35]何浩明，冯岗，尹正康等．乙肝患者外周血B细胞和T细胞及其亚群的研究．临床肝胆病杂志(J)，1996，12(3)：160-162．
[36]叶维法主编．临床肝胆病学(M)．天津：天津出版社，1985：242．
[37]赵耀基，邬祥惠，杨佩珍等．病毒性肝炎血清循环免疫复合物和C3、C4的检测及其意义．中华传染病杂志(J)，1983，1(1)：9-11．
[38]金实，周珉主编．病毒性肝炎中医证治(M)．第一版．北京：人民卫生出版社，2001：438．
[39]Mosmann TR ,Cherwinski H, Bond MW et al. Tow types of murine helper T cell clone 1 difintion according to profiles of lymphokine activities and secreted proteins. Immunol (J) 1986,136:2348-2357.
[40]Yamamura M, Ulyemura K, Deans RJ et al. Defining protective response to pathogens: cytokine profile in lprosy lesions, science (J) ,1991,254:
277-279.
[41] Scott P, Natovitz P, Coffiman RL et al. Immunoregulation of cutaneous leishmaniasis T cell limes that transfer protective immunity or exacerbation belong to different T helper subsets and responsed to distinct parasite antigens. Exp med (J) ,1988,168:1675-1684.
[42] Heinzed FP ,Sadick MD, Hotaday BJ. Reciprocal expression of interferon or interleukin 4 during the resolution or progression of murine leishmaniasis Evidence for expression of distinct helper 7 cell subset. Exp med (J), 1989,169:59-72.
[43] Carding SR ,Allan W ,Mcmickle A et al. Activation of cytokine genes in T cells during primary and secondary murine influence peumonia. Exp med (J) 1993,177:475-482.
[44] Ramsay AJ, Rubby J, Ramshaw LA et al. A case for cytokines as effecter molecules in the resolution of rirus infection .Immumol today (J) 1993,14:155-157.
[45] 宝福凯，柳爱华．IL-12及其在细胞免疫中的作用．国外医学．输血及血液学分册(J)，1995，18(3)：165-169．
[46] Penna A ,Del prete G, Cavalli A et al. Predominant T-helper 1 cytokines prefiles of Hepatitis B virus Nuclecocapsid-specific T cells in a cute self -limited Hepatitis B.Hepatology (J) ,1996,25(4) :1022-1027.
[47] 张树林，刘敏，朱江等．Th2优势应答与HBV慢性感染．世界华人消化杂志(J)，1999，7(6)：1320-1322．
[48] 姜荣龙，卢桥生，骆抗先等．Th1/Th2细胞在慢性乙型肝炎病毒感染中的作用．第一军医大学学报(J)，2000，20(2)：103-105．
[49] 刑同京，章廉，侯金林等．慢性乙肝患者Th1/Th2应答与乙肝病毒感染单个核细胞的关系．第一军医大学学报(J)，2000，20(2)：117-119．
[50] 王文俊，吴成中，姚智等．中药有效成分对IL-2及IFN-γ分泌的影响．天津中医(J)，1995，12(2)：23-24．
[2] Thomas HC, montano L Goodall A et al. Immunological mechanisms in chronic hepatitis B. Virus infection. Hepatology(J),1983;2 (Suppl) :116-121.
[3] Penna A ,Chisan FV, Bertoletti A et al. cytoxic T lymphocytes recognize an HLA -restricted epitope within the hepatitis B virus nucleocapsid antigen. Exp med(J) 1991, 174:1565-1570.
[4] Bertoletti AK, Elios MM, Boni C, et al. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infection. Gastroenterology (J) , 1997, 112(1) :193-199.
[5] Lee M, Lee SK, Son M, et al. Expression of Th1 and Th2 type cytokines responding to HBsAg and HBxAg in chronic hepatitis B patients. Korean Men Sci(J) .1999,14:175-181.
[6] Nishimura T, Ohta A. A critical role for antigen-specific Th1 cells in acute liver injury in mice. Immunol(J),1999,162:6503-6509.
[7] 陈锦芳，李丹，潘晨等．慢肝湿热蕴脾证血瘀的研究．福建中医学院学报(J)，
2000，10(3)：3-5．
[8]病毒性肝炎防治方案．中华传染病杂志(J)，2001，19(1)：56-62．
[9]中药新药临床研究指导原则(第一辑)(M)．中华人民共和国卫生部制定发布，1993：103-106．
[10]陈奇主编．中药药理实验方法(M)．第一版．北京：人民卫生出版社，1994：23-28．
[11]谢秀琼主编．中药新制剂开发与应用(M)．第二版．北京：人民卫生出版社，2000：534—535，540．
[12]Nayersina R etal. Immune(J), 1993, 150:4659-4671.
[13]Rehermann B etal. Exp Med(J),1995,189:1047-1058.
[14]陈复正．幼幼集成(M)．第一版．上海：上海科学技术出版社，1962：162．
[15]单书健，陈子华编著．古今名医临证金鉴．黄疸胁痛臌胀卷(M)．第一版．北京：中国中医药出版社，1998：60，141．
[16]饶闲宜．病毒性肝炎微循环障碍与瘀血的关系．云南中医(J)，1985，3：1．
[17]廖孔禹．活血化瘀法治疗慢性活动性肝炎140例．四川中医(J)，1987，12：18．
[18]解新科，王静，郝明霞．活血化瘀为主治疗慢性乙肝疗效及血液流变学观察．陕西中医学院学报(J)，1999，22(6)17-18．
[19]张赤志，吴寿善，罗欣拉等．肝病血瘀证临床病理学特点和肝功能变化．中国中西医结合杂志(J)，1992，12(4)：210．
[20]张清波．通过外周微循环、血液流变学和免疫功能的观察探讨病毒性肝炎的中医辨证分型．中华医学杂志(J)，1982，62(8)：449—454．
[21]王伯祥主编．活血化瘀药．中医肝胆病学(M)．第一版．北京：中国医药科技出版社，1998：193
[22]徐树楠主编．中药临床应用大全(M)．第一版．河北：河北科学技术出版社，1999：277，646，89，15，588，254，67，54．
[23]刘国华，王健．茵栀黄口服液对实验性肝损伤的药理作用及毒性研究．中药新药与临床药理(J)，1995，6(2)：28—29．
[24]JP(J)．1982，18：622．
[25]蔡宝昌，潘扬，吴皓等．国外天然药物抗病毒研究简况．国外医学．中医中药分册(J)，1997，19(3)：48．
[26]张赤伟，吴在德．丹参对大鼠肝缺血后残肝再生促进作用的初步观察．同济医科大学学报(J)，1995，24(4)：272．
[27]戚心广，稻恒豐．丹参、赤芍对实验性肝损伤肝细胞保护作用的机理研究．中西医结合杂志(J)，1991，11(2)：102．
[28]张万增，董仲德，袁桂玉等．丹参对重型肝炎补体活化的抑制作用．中国中西医结合杂志(J)，1994，14(7)：445．
[29]何敏．白花蛇舌草的研究与应用概况．中医药学报(J)，1994，22(5)：36-39．
[30]单保思，张金艳，杜肖娜等．白花蛇舌草的免疫学调节活性和抗肿瘤活性．中国中西医结合杂志(J)，2001，21(5)：370-374．
[31]王建军，刑秋侠，郭文化等．乙型肝炎患者补体对HBsAg特异性免疫复合物的裂解作用．中国实用临床免疫学杂志(J)，1998，10(4)：222-226．
[32]董薇红，腾天申，吴昌烈等．13种血清蛋白检测在各型肝炎中的临床意义．中华传染病杂志(J)，1994，12(1)：44-45．
[33]蔡望喜，胡传芳，乐惠荣等．慢性乙肝患者红细胞免疫粘附功能和体液免疫功能的观察．中西结合肝病杂志(J)，1999，9(1)：38-39．
[34]高寿征，田庚善，崔振宇等主编．病毒性肝炎防治研究(M)．北京：北京出版社，1993：182，88．
[35]何浩明，冯岗，尹正康等．乙肝患者外周血B细胞和T细胞及其亚群的研究．临床肝胆病杂志(J)，1996，12(3)：160-162．
[36]叶维法主编．临床肝胆病学(M)．天津：天津出版社，1985：242．
[37]赵耀基，邬祥惠，杨佩珍等．病毒性肝炎血清循环免疫复合物和C3、C4的检测及其意义．中华传染病杂志(J)，1983，1(1)：9-11．
[38]金实，周珉主编．病毒性肝炎中医证治(M)．第一版．北京：人民卫生出版社，2001：438．
[39]Mosmann TR ,Cherwinski H, Bond MW et al. Tow types of murine helper T cell clone 1 difintion according to profiles of lymphokine activities and secreted proteins. Immunol (J) 1986,136:2348-2357.
[40]Yamamura M, Ulyemura K, Deans RJ et al. Defining protective response to pathogens: cytokine profile in lprosy lesions, science (J) ,1991,254:
277-279.
[41] Scott P, Natovitz P, Coffiman RL et al. Immunoregulation of cutaneous leishmaniasis T cell limes that transfer protective immunity or exacerbation belong to different T helper subsets and responsed to distinct parasite antigens. Exp med (J) ,1988,168:1675-1684.
[42] Heinzed FP ,Sadick MD, Hotaday BJ. Reciprocal expression of interferon or interleukin 4 during the resolution or progression of murine leishmaniasis Evidence for expression of distinct helper 7 cell subset. Exp med (J), 1989,169:59-72.
[43] Carding SR ,Allan W ,Mcmickle A et al. Activation of cytokine genes in T cells during primary and secondary murine influence peumonia. Exp med (J) 1993,177:475-482.
[44] Ramsay AJ, Rubby J, Ramshaw LA et al. A case for cytokines as effecter molecules in the resolution of rirus infection .Immumol today (J) 1993,14:155-157.
[45] 宝福凯，柳爱华．IL-12及其在细胞免疫中的作用．国外医学．输血及血液学分册(J)，1995，18(3)：165-169．
[46] Penna A ,Del prete G, Cavalli A et al. Predominant T-helper 1 cytokines prefiles of Hepatitis B virus Nuclecocapsid-specific T cells in a cute self -limited Hepatitis B.Hepatology (J) ,1996,25(4) :1022-1027.
[47] 张树林，刘敏，朱江等．Th2优势应答与HBV慢性感染．世界华人消化杂志(J)，1999，7(6)：1320-1322．
[48] 姜荣龙，卢桥生，骆抗先等．Th1/Th2细胞在慢性乙型肝炎病毒感染中的作用．第一军医大学学报(J)，2000，20(2)：103-105．
[49] 刑同京，章廉，侯金林等．慢性乙肝患者Th1/Th2应答与乙肝病毒感染单个核细胞的关系．第一军医大学学报(J)，2000，20(2)：117-119．
[50] 王文俊，吴成中，姚智等．中药有效成分对IL-2及IFN-γ分泌的影响．天津中医(J)，1995，12(2)：23-24．